TNG348 + olaparib

Combination therapy of **TNG348**, a selective allosteric small molecule inhibitor of ubiquitin specific peptidase 1 (USP1), and **olaparib**, a poly (ADP-ribose) polymerase (PARP) inhibitor. This combination targets cancers with **BRCA1/2 mutations** or **homologous recombination deficiency (HRD)**, aiming to exploit synthetic lethality by dual inhibition of DNA damage repair pathways. TNG348 potentiates the antitumor effect of olaparib and demonstrates synergistic growth inhibition in preclinical tumor models by blocking USP1-mediated homologous recombination repair and PARP-mediated base excision repair simultaneously. Principal indication is for advanced or metastatic solid tumors, especially those with BRCA1/2 mutations or HRD, with trial evidence in breast, ovarian, pancreatic, and prostate cancers.

Other names

AZD2281AZD-2281AZD 2281KU-0059436KU0059436KU 0059436KU59436KU-59436KU 59436